Verkaik N S, Schröder F H, Romijn J C
Urol Res. 1997;25(6):373-84. doi: 10.1007/BF01268851.
Understaging is commonly associated with therapeutic failure of surgical intervention in apparently localized prostate cancers. Methods that specifically detect prostate cancer cells in the circulation may be able to identify metastatic cancers and thus aid in the selection of the most adequate therapy. The high sensitivity and specificity of the reverse transcriptase-polymerase chain reaction (RT-PCR) encouraged various groups to investigate the mRNA expression of prostate-specific markers in the peripheral blood of patients with prostate cancer. However, probably due to methodological differences, many contradictory results have been obtained with the markers studied so far: prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSM). For this reason, clinical decisions should not be based yet on RT-PCR results. Future research and long-term follow-up on the patients may point out whether RT-PCR assays, following appropriate standardization, will have an additive value in prostate cancer staging and in prediction of tumor progression.
分期不足通常与明显局限性前列腺癌手术干预的治疗失败相关。能够特异性检测循环中前列腺癌细胞的方法或许能够识别转移性癌症，从而有助于选择最恰当的治疗方法。逆转录聚合酶链反应（RT-PCR）的高灵敏度和特异性促使多个研究团队对前列腺癌患者外周血中前列腺特异性标志物的mRNA表达进行研究。然而，可能由于方法学上的差异，迄今为止在所研究的标志物（前列腺特异性抗原（PSA）和前列腺特异性膜抗原（PSM））方面已获得许多相互矛盾的结果。因此，临床决策目前不应基于RT-PCR结果。对患者的未来研究和长期随访可能会指明，经过适当标准化的RT-PCR检测在前列腺癌分期和肿瘤进展预测中是否具有附加价值。
